文献速递类风湿关节炎脊柱关节炎

风湿性疾病患者暴露于Janus激酶抑制剂与阿达木单抗的胃肠道穿孔风险:一项全国性队列研究

Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2024-05-30

该法国全国性队列研究纳入2017年7月至2021年12月首次使用JAK抑制剂或阿达木单抗的风湿性疾病患者共39,758例,比较胃肠道穿孔风险。JAK抑制剂组与阿达木单抗组胃肠道穿孔发生率分别为2.1/1000人年和1.1/1000人年,加权风险比1.1(95%CI 0.7-1.9;P=0.65),两组无显著差异。作者指出该结果需在其他观察性研究中确认。

要点

  • JAK抑制剂组胃肠道穿孔发生率为2.1/1000人年,阿达木单抗组为1.1/1000人年。
  • 两组胃肠道穿孔风险无显著差异,加权风险比1.1(95%CI 0.7-1.9;P=0.65)。
  • 各JAK抑制剂类型及风湿病亚组结果一致,但部分亚组分析把握度不足。

核心结论

  • 在该全国性队列研究中,接受JAK抑制剂与阿达木单抗治疗的患者胃肠道穿孔发生率无差异。
  • 作者指出这些结果需在其他观察性研究中确认。

研究设计与样本

  • 法国全国性基于人群的队列研究,使用法国国家健康数据系统。
  • 纳入2017年7月至2021年12月首次配发JAK抑制剂(托法替布、巴瑞替尼、乌帕替尼或非戈替尼)或阿达木单抗的所有风湿性疾病患者。
  • 暴露组为接受JAK抑制剂者,对照组为接受阿达木单抗者,共39,758例(JAK抑制剂组12,335例,阿达木单抗组27,423例)。
  • 主要终点为胃肠道穿孔发生(随访截至2022年5月),采用逆概率治疗加权法估计加权风险比以校正混杂因素。
  • 全身性糖皮质激素、非甾体抗炎药和质子泵抑制剂的合并使用作为时变变量。

主要发现

  • JAK抑制剂组平均年龄58.2岁,女性76%,类风湿关节炎85.3%,银屑病关节炎/中轴型脊柱关节炎14.7%;阿达木单抗组平均年龄47.3岁,女性58%,类风湿关节炎27.3%,银屑病关节炎/中轴型脊柱关节炎72.7%。
  • 随访期间JAK抑制剂组发生38例胃肠道穿孔,阿达木单抗组发生42例。
  • JAK抑制剂组胃肠道穿孔发生率为2.1/1000人年(95%CI 1.5-2.8),阿达木单抗组为1.1/1000人年(95%CI 0.8-1.5)。
  • 两组胃肠道穿孔风险无显著差异:加权风险比1.1(95%CI 0.7-1.9;P=0.65)。
  • 尽管部分亚组分析把握度不足,无论接受的JAK抑制剂类型或风湿病类型亚组,结果一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 部分亚组分析把握度不足。
  • 作者指出这些结果需在其他观察性研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of gastrointestinal perforation (GIP), a rare but serious adverse event, in patients who a JAK inhibitor (JAKi; tofacitinib, baricitinib, upadacitinib, or filgotinib) versus adalimumab (tumor necrosis factor inhibitor) among a comprehensive real-world population of patients with rheumatic diseases. METHODS: We conducted a nationwide population-based cohort study of the French national health data system, the exposed group that received a JAKi and the comparison group adalimumab. We included all individuals with a rheumatic disease who had their first dispensation of these treatments from July 2017 to December 2021. The primary endpoint was the occurrence of GIP (end of follow-up May 2022). Weighted hazard ratios (wHRs) were estimated with the inverse probability of treatment weighting method to account for confounding factors. Concomitant administration of systemic glucocorticoids, nonsteroidal anti-inflammatory drugs, and proton-pump inhibitors were time-varying variables. RESULTS: The cohort included 39,758 patients: 12,335 and 27,423 in the groups that received a JAKi and adalimumab (mean age 58.2 and 47.3 years; female 76% and 58%; rheumatoid arthritis 85.3% and 27.3%, and psoriatic arthritis/axial spondyloarthritis 14.7% and 72.7%), respectively. During follow-up, 38 and 42 GIPs occurred in the groups that received a JAKi and adalimumab groups; incidence rates were 2.1 (95% confidence interval [CI] 1.5-2.8) and 1.1 (95% CI 0.8-1.5) per 1,000 person-years, respectively. Rates of GIP did not differ between the groups that received a JAKi and adalimumab: wHR 1.1 (95% CI 0.7-1.9; P = 0.65). Despite the lack of power in some subgroup analyses, results were consistent whatever the subgroup of a type of JAKi received or subgroup with a type of rheumatic disease. CONCLUSION: In this nationwide cohort study, the rates of GIPs did not differ between groups of patients who received JAKi and adalimumab treatment. These results need to be confirmed in other observational studies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hoisnard L, Meyer A, Dray-Spira R, et al. Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study. Arthritis Rheumatol. 2024. PMID: 38699822. doi:10.1002/art.42862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。